JPM Week – San Francisco

January, 2023

In the first global sharing of its innovative solution for anaphylaxis treatment, De Motu Cordis (DMC) reports progress on its dry powder inhaler (DPI) containing epinephrine (adrenaline) for inhaled anaphylaxis treatment.

DMC Chief Medical Officer, Professor John Fraser, shared progress and outcomes from Phase I clinical studies, where plasma epinephrine concentration reached Cmax 8 times faster compared to a widely used autoinjector.

Improved treatment of anaphylaxis, without needles information sheet